NIDDK-funded Study Finding: Researchers Report Characteristics in Children with VUR
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-funded researchers found that a cohort of children enrolled in the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial have similar demographic and clinical characteristics to those in previously published U.S. studies. RIVUR is the largest prospective, randomized trial to date comparing prophylaxis with placebo in children with vesicoureteral reflux (VUR). The ongoing trial addresses the lack of a placebo or observational arm in previous studies and aims to collect higher-quality evidence for preventing recurrent urinary tract infections (UTIs) in children with VUR.
Investigators at 19 pediatric U.S. sites recruited 558 girls and 49 boys with grades I through IV VUR. The median age was 12 months, and 91 percent of the children were enrolled after their first UTI. Renal cortical defects were identified in 15 percent of participants. Similar to previous U.S. studies, 91 percent of children were females, and 80 percent were Caucasian. More than 90 percent of children in this study cohort and previous U.S. studies had grade III or lower VUR; the majority of these children had grade II or grade III VUR.
New Treatment Approved for Overactive Bladder
Overactive bladder, a common condition in which the bladder squeezes either too often or without warning, affects 33 million men and women in the United States. Symptoms include leaking urine (urinary incontinence), feeling the sudden and urgent need to urinate, and frequent urination. The U.S. Food and Drug Administration’s expanded use of Botox to treat adults with overactive bladder provides a new, important treatment option for those affected by this condition.
Botox’s safety and effectiveness for this new indication were established in two clinical trials of 1,105 patients with symptoms of overactive bladder. Treatment with Botox can be repeated when the benefits from the previous treatment have decreased, but there should be at least 12 weeks between treatments.
New and Updated Publications
- Diet for Kidney Stone Prevention
- Kidney Stones in Adults
- Lupus Nephritis
- The Kidney Failure Glossary (Spanish)
- What I need to know about Kidney Stones
Page last updated September 4, 2013